Phase 2 Trial of Dose Dense (Weekly) Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Recurrent Ovarian Cancer

Trial ID # NCT02440425
Phase II
Drug Class Immunotherapy: Checkpoint Inhibitors/PD-1
Drug Name Pembrolizumab
Alternate Drug Names Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475
Drugs in Trial Paclitaxel, Pembrolizumab
Eligible Participant

Platinum resistant ovarian cancer

Patients Enrolled


Therapy Setting


Study Design

Open-Label, Non-randomized


ORR, PFS, OS, evaluated per RECIST


ORR: 51.4%
PFS: 6.7 months
OS: 13.4 months
PFS (6 months): 52.5%


Pembrolizumab+paclitaxel shows improved ORR and PFS compared to historical results with paclitaxel


Wenham RM et al. Phase 2 trial of weekly paclitaxel with pembrolizumab in platinum resistant recurrent ovarian cancer. Intl J Gynecol Cancer (2018) 28 (Suppl 2) 1-1258  

Combinations Will Lead the Way in Immunotherapy for Ovarian Cancer, Onc LIve SGO WInter Meeting Conference Coverage, 2/10/2020

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.